ClinicalTrials.gg
Enrolling by invitationNCT07847905LM364Updated Nov 10, 2026

A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of LM-364 for injection and Tislelizumab in Advanced Solid Tumor Cancer, sponsored by LaNova Medicines Limited. Enrolling by invitation at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now Enrolling by invitationStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.

For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor Cancer
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Participants must be ≥18 years or the legal age of consent at the time of signing the ICF.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. Adequate organ and bone marrow function as defined by protocol.
  6. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participant in any other clinical trial within 28 days prior to 1st dosing of LM-364.
  2. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of v6.0.
  3. Participants with uncontrolled tumour-related pain.
  4. Use of any within 28 days prior to 1st dosing of LM-364.
  5. Participants who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-364.
  6. Participants who have severe cardiovascular disease.
  7. Participants who have uncontrolled or severe illness.
  8. Participants who have a history of immunodeficiency disease.
  9. Participants with a known history of disease.
  10. female who have positive results in pregnancy test or are lactating.
  11. Participants who have psychiatric illness or disorders that may preclude study compliance.
  12. Participants who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    LM-364 Monotherapy

    Drug: LM-364 for injection

  • Experimental
    LM-364 Combination Therapy

    Drug: LM-364 for injection · Drug: Tislelizumab

Interventions

  • DrugLM-364 for injection

    Q3W, Intravenous infusion

  • Q3W, Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Phase I

    Time frame: 78 Weeks

  2. Adverse events (AEs)

    Phase I

    Time frame: 78 weeks

  3. serious adverse events (SAEs)

    Phase I

    Time frame: 78 weeks

  4. Temperatures

    Phase I

    Time frame: 78 weeks

  5. Pulse in BPM

    Phase I

    Time frame: 78 weeks

  6. Blood Pressure in mmHg

    Phase I

    Time frame: 78 weeks

  7. Weight in Kg

    Phase I

    Time frame: 78 weeks

  8. Height in centimeter

    Phase I

    Time frame: 78 weeks

  9. Laboratory examinations--Blood Routine examination-Complete Blood Count

    Phase I

    Time frame: 78 weeks

  10. Laboratory examinations--Blood biochemistry- Electrolytes and Metabolic Parameters

    Phase I

    Time frame: 78 weeks

  11. Laboratory examinations-Urine Routine test-Urinalysis

    Phase I

    Time frame: 78 weeks

  12. Laboratory examinations--Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)

    Phase I

    Time frame: 78 weeks

  13. Laboratory examinations--Thyroid function-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)

    Phase I

    Time frame: 78 weeks

  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase I

    Time frame: 78 weeks

  15. 12-lead electrocardiogram (ECG) in HR

    Phase I

    Time frame: 78 weeks

  16. 12-lead electrocardiogram (ECG) in RR

    Phase I

    Time frame: 78 weeks

  17. 12-lead electrocardiogram (ECG) in PR

    Phase I

    Time frame: 78 weeks

  18. 12-lead electrocardiogram (ECG) in QRS

    Phase I

    Time frame: 78 weeks

  19. 12-lead electrocardiogram (ECG) in QT

    Phase I

    Time frame: 78 weeks

  20. 12-lead electrocardiogram (ECG) in QTcF

    Phase I

    Time frame: 78 weeks

  21. ECOG score-Cooperative Oncology Group score

    Phase I

    Time frame: 78 weeks

  22. Objective Response Rate (ORR)

    Phase II

    Time frame: 52 weeks

Secondary outcomes

  1. PK Parameter: Area Under the Concentration-time Curve(AUC)

    Phase I/II

    Time frame: 130 week

  2. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase I/II

    Time frame: 130 weeks

  3. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase I/II

    Time frame: 130 weeks

  4. PK Parameter: Elimination Half-life (T1/2)

    Phase I/II

    Time frame: 130 weeks

  5. PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase I/II

    Time frame: 130 weeks

  6. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase I/II

    Time frame: 130 weeks

  7. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase I/II

    Time frame: 130 weeks

  8. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase I/II

    Time frame: 130 weeks

  9. PK Parameter: Accumulation Ratio (Rac)

    Phase I/II

    Time frame: 130 weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Phase I/II

    Time frame: 130 weeks

  11. Immunogenicity testing-Anti-drug antibody

    Phase I/II

    Time frame: 130 weeks

  12. Immunogenicity testing-neutralizing antibody (Nab)

    Phase I/II

    Time frame: 130 weeks

  13. Objective response rate (ORR)

    Phase I

    Time frame: 78 weeks

  14. Duration of response (DOR)

    Phase I/II

    Time frame: 130 weeks

  15. Disease control rate (DCR = CR + PR + SD)

    Phase I/II

    Time frame: 130 weeks

  16. Progression free survival according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Phase I/II

    Time frame: 130 weeks

  17. Overall survival (OS)

    Phase I/II

    Time frame: 130 weeks

  18. Changes of target lesions from baseline in Millimeter

    Phase I/II

    Time frame: 130 weeks

  19. QTc-PK relationship -> Correlation concentrations (total antibody, free DXd) vs ΔQTcF (Fridericia's correction)

    Phase I

    Time frame: 78 weeks

  20. Incidence of adverse events (AEs)

    Phase II

    Time frame: 52 weeks

  21. Incidence of serious adverse events (SAEs)

    Phase II

    Time frame: 52 weeks

  22. Temperature (Celsius)

    Phase II

    Time frame: 52 weeks

  23. Pulse in BPM(Beat per Minute)

    Phase II

    Time frame: 52 weeks

  24. Blood Pressure in mmHg

    Phase II

    Time frame: 52 weeks

  25. Weight in Kg

    Phase II

    Time frame: 52 weeks

  26. Height in centimeters

    Phase II

    Time frame: 52 weeks

  27. Laboratory examinations--Blood Routine examination-Complete Blood Count

    Phase II

    Time frame: 52 weeks

  28. Laboratory tests-Urine Routine test-Urinalysis

    Phase II

    Time frame: 52 weeks

  29. Laboratory tests-Blood biochemistry- Electrolytes and Metabolic Parameters

    Phase II

    Time frame: 52 weeks

  30. Laboratory tests- Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)

    Phase II

    Time frame: 52 weeks

  31. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase II

    Time frame: 52 weeks

  32. 12-lead electrocardiogram (ECG) in HR

    Phase II

    Time frame: 52 weeks

  33. 12-lead electrocardiogram (ECG) in RR

    Phase II

    Time frame: 52 weeks

  34. 12-lead electrocardiogram (ECG) in PR

    Phase II

    Time frame: 52 weeks

  35. 12-lead electrocardiogram (ECG) in QRS

    Phase II

    Time frame: 52 weeks

  36. 12-lead electrocardiogram (ECG) in QT

    Phase II

    Time frame: 52 weeks

  37. 12-lead electrocardiogram (ECG) in QTcF

    Phase II

    Time frame: 52 weeks

  38. Eastern Cooperative Oncology Group score

    Phase II

    Time frame: 52 weeks

Other outcomes

  1. To explore the relationship between the biomarkers including Nectin-4 expression and the anti-tumor activity

    Phase I/II

    Time frame: 130 weeks

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Oct 2030, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartActual
Oct 20, 2026
Primary completionEst.
Oct 19, 2030
CompletionEst.
Aug 19, 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 10, 2026
Sites
1 site removed
Show 1 removed
  • Hunan cancer hospital · Changsha, China
Nov 10, 2026
Start date
Oct 19, 2026→Oct 20, 2026 (actual)
Nov 10, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedLaboratory examinations--Blood Routine examination-Complete Blood CountTime frame: 78 weeks
  • EditedLaboratory examinations--Blood biochemistry- Electrolytes and Metabolic ParametersTime frame: 78 weeks
  • EditedLaboratory examinations-Urine Routine test-UrinalysisTime frame: 78 weeks
  • ChangedBefore Laboratory examinations--Coagulation functionNow Laboratory examinations--Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)Time frame: 78 weeks
  • ChangedBefore Laboratory examinations--Thyroid functionNow Laboratory examinations--Thyroid function-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)Time frame: 78 weeks
Oct 14, 2026
Secondary outcomes
4 edited, 1 removed
What changed in the outcomes
  • EditedLaboratory examinations--Blood Routine examination-Complete Blood CountTime frame: 52 weeks
  • EditedLaboratory tests-Urine Routine test-UrinalysisTime frame: 52 weeks
  • EditedLaboratory tests-Blood biochemistry- Electrolytes and Metabolic ParametersTime frame: 52 weeks
  • ChangedBefore Laboratory tests- Coagulation functionNow Laboratory tests- Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)Time frame: 52 weeks
  • RemovedTo analysis the metabolites of LM-364 if possibleTime frame: 78 weeks
Oct 14, 2026
Contact
No study contact listed any more: removed A•••@lanovamed.com · •••5211
Nov 10, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, ChinaContact removed (no phone or email listed)
  • the first affiliated hospital of Henan medical University · Xinxiang, ChinaContact removed (no phone or email listed)
  • Taihe Hospital Affiliated Hospital of Hubei University of Medicine · Shiyan, ChinaContact removed (no phone or email listed)
  • Hunan cancer hospital · Changsha, ChinaContact removed (no phone or email listed)
  • Liaocheng People's Hospital · Liaocheng, ChinaContact removed (no phone or email listed)
  • FuDan University Shanghai Cancer Center · Shanghai, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • The First School of Medicine, School of Information and Engineering,The First Affliated Hospital of Wenzhou Medical University · Wenzhou, ChinaContact removed (no phone or email listed)
Nov 10, 2026
Title
A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Oct 14, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 3 updates
  1. Nov 10, 2026
    Not yet recruiting→Enrolling by invitation
    1 site removed
    Show 1 removed
    • Hunan cancer hospital · Changsha, China
    Start date Oct 19, 2026→Oct 20, 2026 (now actual)
    Contact No study contact listed any more: removed A•••@lanovamed.com · •••5211
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, ChinaContact removed (no phone or email listed)
    • the first affiliated hospital of Henan medical University · Xinxiang, ChinaContact removed (no phone or email listed)
    • Taihe Hospital Affiliated Hospital of Hubei University of Medicine · Shiyan, ChinaContact removed (no phone or email listed)
    • Hunan cancer hospital · Changsha, ChinaContact removed (no phone or email listed)
    • Liaocheng People's Hospital · Liaocheng, ChinaContact removed (no phone or email listed)
    • FuDan University Shanghai Cancer Center · Shanghai, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • The First School of Medicine, School of Information and Engineering,The First Affliated Hospital of Wenzhou Medical University · Wenzhou, ChinaContact removed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 14, 2026
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedLaboratory examinations--Blood Routine examination-Complete Blood CountTime frame: 78 weeks
    • EditedLaboratory examinations--Blood biochemistry- Electrolytes and Metabolic ParametersTime frame: 78 weeks
    • EditedLaboratory examinations-Urine Routine test-UrinalysisTime frame: 78 weeks
    • ChangedBefore Laboratory examinations--Coagulation functionNow Laboratory examinations--Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)Time frame: 78 weeks
    • ChangedBefore Laboratory examinations--Thyroid functionNow Laboratory examinations--Thyroid function-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)Time frame: 78 weeks
    Secondary outcomes 4 edited, 1 removed
    What changed in the outcomes
    • EditedLaboratory examinations--Blood Routine examination-Complete Blood CountTime frame: 52 weeks
    • EditedLaboratory tests-Urine Routine test-UrinalysisTime frame: 52 weeks
    • EditedLaboratory tests-Blood biochemistry- Electrolytes and Metabolic ParametersTime frame: 52 weeks
    • ChangedBefore Laboratory tests- Coagulation functionNow Laboratory tests- Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)Time frame: 52 weeks
    • RemovedTo analysis the metabolites of LM-364 if possibleTime frame: 78 weeks
    Title A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
  3. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847905
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 20, 2026
Primary completion
Oct 19, 2030 (estimated)
Completion
Aug 19, 2031 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion